With the expanded approval, Novartis’ drug entered the IgA nephropathy (IgAN) market and will compete with Swedish drugmaker Calliditas’ Tarpeyo and Travere Therapeutics’ Filspari.
News
US FDA approves Novartis’ kidney disease drug
August 9, 2024
With the expanded approval, Novartis’ drug entered the IgA nephropathy (IgAN) market and will compete with Swedish drugmaker Calliditas’ Tarpeyo and Travere Therapeutics’ Filspari.